Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Emblem Corp    EMC   CA29082J1084

EMBLEM CORP (EMC)
My previous session
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Financials (CAD)
Sales 2018 10,2 M
EBIT 2018 -15,4 M
Net income 2018 -17,7 M
Debt 2018 3,30 M
Yield 2018 -
Sales 2019 40,8 M
EBIT 2019 3,72 M
Net income 2019 -0,91 M
Debt 2019 10,7 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 21,7x
EV / Sales2019 5,59x
Capitalization 218 M
More Financials
Company
Emblem Corp. engages in the sale of cannabis to patients who have received medical authorizations to acquire and use such cannabis.Its activities include production and sale of dried cannabis to qualified patients.The Company was founded on February 25, 2008 and is headquartered in Toronto, Canada. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of Emblem Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on EMBLEM CORP
10:27aCANNTAB AND EMBLEM ANNOUNCE POSITIVE : Proceeding to Clinical Trials
AQ
09/183 Pot Stocks On The Move After Latest Industry News
AC
09/18EMBLEM : and Canntab to Commence Clinical Testing of 12-Hour Extended Release Ca..
AQ
09/15EMBLEM : and Natura Naturals announce termination of letter of intent
AQ
09/14EMBLEM : launches Atmosphere, its first oral dose-metered spray
AQ
09/14EMBLEM : and Natura Naturals announce termination of letter of intent
AQ
09/13Global Cannabis Partnership Welcomes New Members
AQ
09/133 Marijuana Stocks in the News this Week
AC
09/13EMBLEM : signs supply agreement with Aphria to purchase up to 175,000 kg equival..
AQ
09/13EMBLEM : launches Atmosphere, its first oral dose-metered spray
AQ
More news
Sector news : Alternative Medicine
07:53pCOCA COLA : moving ahead with takeover of Nigeria's Chi juice
RE
07:20pNOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
03:31pGerman chemical industry warns against disruptive no-deal Brexit
RE
02:12pNOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
01:44pGILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
More sector news : Alternative Medicine
News from SeekingAlpha
08/29THE BIGGEST RISK FOR CANOPY GROWTH : Oversupply 
08/27WEEKLY CANNABIS REPORT : Diageo Fuels Speculation; Ontario Picks 26 Suppliers 
08/22Emblem reports Q2 results 
07/26Emblemsigns letter of intent to acquire Natura Naturals 
07/24Horizons Emerging Marijuana Growers ETF HMJR - 2018 Q2 Update 
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 2,45  CAD
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Nick Dean President, Chief Executive Officer & Director
Harvey Shapiro Chairman, Secretary & Vice President
Daniel Saperia Chief Operating Officer
Alex Stojanovic Chief Financial Officer
Maxim Zavet Director
Sector and Competitors
1st jan.Capitalization (M$)
EMBLEM CORP167
CANOPY GROWTH CORP126.40%11 073
AURORA CANNABIS INC14.79%7 279
BEIJING TONGRENTANG CO., LTD.-6.85%5 877
DONG-E-E-JIAO CO LTD--.--%4 156
HUTCHISON CHINA MEDITECH LIMITED-22.32%3 782